Dr. Van Zee on Prevention of Invasive Recurrence in Breast Cancer

Video

Kimberly Van Zee, MD, discusses the importance of preventing invasive recurrence in patients with breast cancer at the 21st Annual Lynn Sage Breast Cancer Symposium.

Kimberly Van Zee, MD, an attending surgeon in the Department of Breast Cancer at Memorial Sloan Kettering Cancer Center and professor of Surgery at the Weill Cornell Medical College, discusses the importance of preventing invasive recurrence in patients with breast cancer at the 21st Annual Lynn Sage Breast Cancer Symposium.

Because there are such wide variations in the recurrence rate and quality of life among the different treatment options for these patients, physicians can find the decision making process very difficult, says Van Zee. The goal of any treatment, however, is to prevent recurrence because half of all recurrences will be invasive.

Overall survival data in all studies have been excellent, so treatment decisions will be made based on local recurrences rather than survival, Van Zee adds. Since local recurrence is associated with a lower risk of invasive recurrence and a lower risk of needing chemotherapy, as well as having a survival impact.

<<< View more from the 2019 Lynn Sage Breast Cancer Symposium

Related Videos
Video 5 - "AE Management with CDK4/6 Inhibitors: Strategies for Treatment Continuity and Optimal Patient Outcomes"
Rita Nanda, MD
Siddartha Yadav, MD, FACP
Nan Chen, MD
Video 4 - "The Evolving Treatment Landscape with CDK4/6 Inhibitors in Early HR+/HER2- Breast Cancer"
Margaret E. Gatti-Mays, MD, MPH, FACP, of The Ohio State University Comprehensive Cancer Center
Ko Un “Clara” Park, MD
Erin Frances Cobain, MD
Video 3 - "5-Year Data from the MonarchE Trial Investigating Abemaciclib in HR+, HER2- High-Risk, Early Breast Cancer"
Pasi A. Jänne, MD, PhD, discusses an exploratory analysis from the FLAURA2 trial of osimertinib plus chemotherapy in treatment-naive, EGFR-mutant NSCLC.